Figure 4.

CAGE binding to Beclin1 occurs in anti-cancer drug-resistant cancer cells and serves as a target of CAGE-derive peptide. (A) Cell lysates from the indicated cancer cells were subjected to immunoblot and immunoprecipitation. (B) PC-9 cells were treated without or with erlotinib (20 μM) or osimertinib (5 μM) for 24 h followed by immunoprecipitation. (C) PC-9/ER cells were transfected with AQTGTGKT peptide (10 μM) for 24 h followed by immunoblot and immunoprecipitation. (D) PC-9/ER cells were transfected with AQTGTGKT peptide (10 μM) for 24 h followed by immunofluorescence staining. ^**p < 0.005.